Select a Region North America

News Alert: ICER Reviews MyoKardia & Bristol-Myers Squibb’s Mavacamten in HCM

PRICENTRIC BRIEF:

  • In its newly published Evidence Report, the Institute for Clinical and Economic Review (ICER) said MyoKardia and Bristol-Myers Squibb’s mavacamten may offer important health benefits in the treatment of hypertrophic cardiomyopathy (HCM)
  • David Rind, MD, ICER’s Chief Medical Officer, stated, “The evidence suggests that mavacamten may deliver important health benefits for patients with a lower rate of side effects than seen with other medications for HCM, but clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction in some patients”
  • ICER noted a health-benefit price benchmark (HBPB) of $12,000 – $15,000 per year, much lower than some industry analysts’ forecasted price of $75,000

THE DETAILS

BOSTON, United States — In its newly published Evidence Report, the Institute for Clinical and Economic Review (ICER) said MyoKardia and Bristol-Myers Squibb’s mavacamten may offer important health benefits in the treatment of hypertrophic cardiomyopathy (HCM).

David Rind, MD, ICER’s Chief Medical Officer, stated, “The evidence suggests that mavacamten may deliver important health benefits for patients with a lower rate of side effects than seen with other medications for HCM, but clinical experts differ in their opinions about the long-term clinical implications of mavacamten reducing left ventricular ejection fraction in some patients.”

Rind said this division in opinions will take center stage at a virtual public meeting of the California Technology Assessment Forum (CTAF) on October 22, 2021, the live stream of which you can register for here.

ICER stated the evidence regarding mavacamten was promising but inconclusive (P/I) to determine if the drug added to first-line therapy provides a net health benefit over first-line therapy care alone or the addition of disopyramide.

The institute did not formally compare mavacamten to septal reduction therapies like alcohol septal ablation and myectomy due to the likely difference in timing of risks and benefits and the resulting diversity among individual patient preferences.

Mavacamten is yet to receive approval from the U.S. Food and Drug Administration (FDA), and its price remains to be announced by its manufacturers.

ICER noted a health-benefit price benchmark (HBPB) of $12,000 – $15,000 per year, much lower than some industry analysts’ forecasted price of $75,000.

Detailed responses to public comments on a draft version of this report can be found here.

 

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.